Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Nataly Tarasenko"'
Publikováno v:
Pharmaceuticals, Vol 14, Iss 12, p 1244 (2021)
We studied the unique inhibitor of the histone deacetylases (HDAC) valproate-valpromide of acyclovir (AN446) that upon metabolic degradation release the HDAC inhibitor (HDACI) valproic acid (VPA). Among the HDAC inhibitors that we have tested, only A
Externí odkaz:
https://doaj.org/article/e14d77353fc84bfe98af7e22dbc9097a
Autor:
Lilach Moyal, Nataly Feldbaum, Neta Goldfeiz, Ada Rephaeli, Abraham Nudelman, Michal Weitman, Nataly Tarasenko, Batia Gorovitz, Leah Maron, Shiran Yehezkel, Iris Amitay-Laish, Ido Lubin, Emmilia Hodak
Publikováno v:
PLoS ONE, Vol 11, Iss 1, p e0146115 (2016)
The 2 histone deacetylase inhibitors (HDACIs) approved for the treatment of cutaneous T-cell lymphoma (CTCL) including mycosis fungoides/sezary syndrome (MF/SS), suberoylanilide hydroxamic acid (SAHA) and romidepsin, are associated with low rates of
Externí odkaz:
https://doaj.org/article/9ab3cb25672a40d497fe1695f1a53697
Autor:
Nataly Tarasenko, Suzanne M Cutts, Don R Phillips, Aida Inbal, Abraham Nudelman, Gania Kessler-Icekson, Ada Rephaeli
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e31393 (2012)
The histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) synergizes the cytotoxic effect of doxorubicin (Dox) and anti-HER2 on mammary carcinoma cells while protecting normal cells against their insults. This study investig
Externí odkaz:
https://doaj.org/article/dcc0d7c2dbf64f00a5e9eb8a6a71bb84
Autor:
Neta, Moskovits, Ella, Itzhaki, Nataly, Tarasenko, Eva, Chausky, Avital, Bareket-Samish, Aleksandr, Kaufman, Raisa, Meerson, Salomon M, Stemmer
Publikováno v:
Journal of Visualized Experiments.
Despite remarkable advances in understanding tumor biology, the vast majority of oncology drug candidates entering clinical trials fail, often due to a lack of clinical efficacy. This high failure rate illuminates the inability of the current preclin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::510f268d464b466708deafb3089779df
https://doi.org/10.3791/64564
https://doi.org/10.3791/64564
Publikováno v:
Pharmaceuticals; Volume 14; Issue 12; Pages: 1244
Pharmaceuticals, Vol 14, Iss 1244, p 1244 (2021)
Pharmaceuticals
Pharmaceuticals, Vol 14, Iss 1244, p 1244 (2021)
Pharmaceuticals
We studied the unique inhibitor of the histone deacetylases (HDAC) valproate-valpromide of acyclovir (AN446) that upon metabolic degradation release the HDAC inhibitor (HDACI) valproic acid (VPA). Among the HDAC inhibitors that we have tested, only A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ee445018f36f12b0e0d04998777ce2b
Autor:
Neta, Moskovits, Idit, Peretz, Eva, Chausky, Ella, Itzhaki, Nofar, Shmuel, Raisa, Meerson, Nataly, Tarasenko, Aleksandr, Kaufman, Amos, Stemmer, Ranny, Yaffe, Avital, Bareket-Samish, Natalia, Edison, Tal, Goldman, Salomon M, Stemmer
Publikováno v:
Cancer Letters. 536:215665
The efficacy/safety of combining palbociclib (a CDK4/6 inhibitor) and sunitinib (a multi-targeted receptor tyrosine kinase inhibitor) was evaluated, using patient-derived xenograft (PDX) models. Twenty-three PDX mice models were developed from patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee2cb7ea8dd38df16ce980e0cc6afb43
https://doi.org/10.1016/j.canlet.2022.215665
https://doi.org/10.1016/j.canlet.2022.215665
Autor:
Yael Ziv, Lilach Moyal, Nataly Tarasenko, Abraham Nudelman, Emmilia Hodak, Efrat Tal, Ada Rephaeli, Batia Gorovitz, Neta Goldfeiz
Publikováno v:
Investigational New Drugs. 36:1-9
We previously found that the novel histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) had greater selectivity against cutaneous T-cell lymphoma (CTCL) than SAHA. AN-7 synergizes with doxorubicin (Dox), an anthracycline an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58ba212dbfd16187a805123381bdf1e8
https://doi.org/10.1007/s10637-017-0500-x
https://doi.org/10.1007/s10637-017-0500-x
Publikováno v:
Investigational New Drugs. 35:412-426
The histone deacetylase (HDAC) inhibitory prodrugs of butyric (AN7) and valproic (AN446) acids, which release the active acids upon metabolic degradation, were studied examining their differential effects on the viability, HDAC inhibitory activity an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0d32da71db98c130f073201951e78d2
https://doi.org/10.1007/s10637-017-0448-x
https://doi.org/10.1007/s10637-017-0448-x
Autor:
Mor Dahbash, Tami Livnat, Ruti Sella, Nataly Tarasenko, Ada Rephaeli, Yael Nisgav, Elinor Megiddo-Barnir, Dov Weinberger
Publikováno v:
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 20, Iss 3, p 714 (2019)
Volume 20
Issue 3
International Journal of Molecular Sciences, Vol 20, Iss 3, p 714 (2019)
Volume 20
Issue 3
Choroidal neovascularization (CNV) is a complication of age-related macular degeneration and a major contributing factor to vision loss. In this paper, we show that in a mouse model of laser-induced CNV, systemic administration of Butyroyloxymethyl-d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::361d5dcf8352007201eb72de297cca93
https://pubmed.ncbi.nlm.nih.gov/30736437
https://pubmed.ncbi.nlm.nih.gov/30736437
Autor:
Abraham Nudelman, Gabriela Rozic, Svetlana Furman, Eitan Fibach, Ada Rephaeli, Nataly Tarasenko, Zvi Malik, Ido Lubin, Julia Lipovetsky
Publikováno v:
European Journal of Pharmaceutical Sciences. 91:91-97
Anemia is a major cause of morbidity and mortality worldwide resulting from a wide variety of pathological conditions. In severe cases it is treated by blood transfusions or injection of erythroid stimulating agents, e.g., erythropoietin (Epo), which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::091abf988287ff8f503fca4eedc4396d
https://doi.org/10.1016/j.ejps.2016.06.004
https://doi.org/10.1016/j.ejps.2016.06.004